BenevolentAI is a clinical-stage drug discovery company seeking to combine artificial intelligence and machine learning with science to decipher complex disease biology, generate new insights and discover more effective medicines. The company’s computational R&D platform spans each step of the drug discovery process, with a focus on novel disease targets discovery.